Reprint of “Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe?”

@article{Stanczyk2015ReprintO,
  title={Reprint of “Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe?”},
  author={F. Stanczyk and B. Bhavnani},
  journal={The Journal of Steroid Biochemistry and Molecular Biology},
  year={2015},
  volume={153},
  pages={151-159}
}
Medroxyprogesterone acetate (MPA) has been in clinical use for over 30 years, and was generally considered to be safe until the results of long-term studies of postmenopausal hormone therapy (HT) using treatment with conjugated equine estrogens (CEE) combined with MPA and CEE alone suggested that MPA, and perhaps other progestogens, may play a role in the increased risk of breast cancer and cardiovascular diseases. This review examines critically the safety of MPA in terms of breast cancer and… Expand
The other side of progestins: effects in the brain.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.
  • R. Cobin, N. Goodman
  • Medicine
  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2017

References

SHOWING 1-10 OF 82 REFERENCES
Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression.
...
1
2
3
4
5
...